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2258Framingham, Massachusetts), 6 (7%) Jarvik 2000 (Jarvik Heart,
New York, New York), 5 (6%) VentrAssist (Ventracor Ltd,
Chatswood, NSW, Australia), and 2 (3%) Levacor (WorldHeart,
Salt Lake City, Utah) LVADs. There were no signiﬁcant differ-
ences in the degree of LV unloading, speciﬁcally right atrial pres-
sure (p ¼ 0.76), mean pulmonary artery pressure (p ¼ 0.20),
pulmonary vascular resistance (p ¼ 0.40), pulmonary capillary
wedge pressure (p ¼ 0.33), and cardiac index (p ¼ 0.26), among
the various types of devices (overall p value was obtained by
Kruskal-Wallis test). Similarly, when examining the distribution of
patients who achieved an LV ejection fraction 40%, we found no
signiﬁcant difference between individual device types (p ¼ 0.12).
We agree that diverse and complex pathophysiological mecha-
nisms might be responsible for the structural and functional
beneﬁts observed with LVAD unloading. We have recently
summarized information from various groups, including our own,
that examined the effects of LVAD unloading on calcium cycling,
contractile function, metabolism and bioenergetics, beta-adrenergic
signaling, cytokines, cytoskeletal proteins, ﬁbrosis, myocyte
hypertrophy, and gene expression (4). However, due to the limited
data correlating structure and function, it is difﬁcult to discern
between structural, cellular, and molecular changes that uniformly
occur in LVAD patients regardless of possible myocardial recovery
and changes that occur exclusively in patients with LVAD-induced
myocardial functional recovery. Therefore, large-scale, translational
studies comprehensively evaluating and correlating functional and
clinical outcomes with cellular, structural, molecular, and other
biological outcomes are urgently needed to identify the clinical and
biological signatures of LVAD-induced myocardial recovery that
will further improve our prognostic capacity and allow for the
identiﬁcation of new therapeutic strategies to augment myocardial
recovery and regeneration.Omar Wever-Pinzon, MD
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Tricuspid Regurgitation by
Caval Valve Implantation
From Technical Feasibility to
Evaluation of Efﬁcacy
We congratulate Laule et al. (1) for the ﬁrst reported use of the
29-mm Edwards Sapien XT balloon-expandable valve (Edwards
Lifesciences, Irvine, California) for transcatheter venous implan-
tation to treat tricuspid regurgitation (TR). However, when we
ﬁrst investigated and clinically applied the concept of caval valve
implantation (CAVI) as a management option for severe TR, we
observed major hemodynamic and anatomic limitations that should
be considered when selecting patients for this approach (2–6). First,
CAVI does not address TR itself but the regurgitation of blood
into the caval veins. Because this condition is present only in a
subgroup of patients with severe, often long-standing TR and right
ventricular (RV) enlargement, hemodynamic proof of caval regur-
gitation is essential before valve implantation. Second, CAVI in-
creases RV afterload by exclusion of backward regurgitation. Thus,
this novel approach should be reserved for patients with preserved
RV systolic function and without elevated pulmonary vascular
resistance. In the aforementioned patient group, there is consid-
erable variation in the anatomic diameter of the inferior vena
cava (IVC), which may reach up to 45 mm. The diameter of the
IVC usually exceeds the suitable range for implantation of current,
commercially available devices. Therefore, these patients require
speciﬁcally designed, potentially individualized devices, which are
currently not commercially available. In the series presented by
Laule et al, the IVC diameter was within the range to allow im-
plantation of 29-mm balloon-expandable devices, whichdfrom
our experiencedcontradicts “hemodynamically” severe TR.
Further issues in the article by Laule et al. (1) deserve clariﬁca-
tion. First, the clinical beneﬁt observed in these patients, particu-
larly the reduction of edema and ascites, is frequently affected by
the improved medical therapy and close clinical follow-up they
are given. In the data presented, there is no obvious change in
echocardiographic parameters to substantiate clinical improvement.
Improved RV function as stated in the text is not supported by
the data presented and is unlikely for the aforementioned reasons.
Lack of documentation of pressure-derived parameters such as
RV end-diastolic pressure and mean right atrial pressure further
complicates the justiﬁcation of procedure-related clinical improve-
ment. Second, the authors unfortunately did not present imaging
studies or invasive hemodynamic data demonstrating function of
both valves. Considering the overall status of the patients, we
consider this information essential to actually support the hemody-
namic and clinical beneﬁt in these patients.
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26, 2013.ReplyManagement of Tricuspid Regurgitation
by Caval Valve Implantation
From Technical Feasibility to
Evaluation of Efﬁcacy
We appreciate the comments by Dr. Lauten and colleagues on
our caval vein approacheswith theEdwards SapienXTvalve (Edwards
Lifesciences, Irvine, California) to treat severe secondary tricuspid
regurgitation (STR) (1), and we welcome the opportunity to reply to
their letter. Since the publication of our letter, we have performed 4
additional procedures, with the result that our experience now includes
7 patients, with follow-ups ranging between 1 and 14 months.
We agree that caval valve implantation (CAVI) is restricted to
STR. Relevant regurgitation into hepatic and caval veins can easily
be veriﬁed by clinical examination and ultrasound Doppler ﬂow
proﬁles. Indeed, although CAVI does not affect tricuspid regurgi-
tation, the allegedly compromising heterotopic inferior vena cava
(IVC) single-vein approach offers a number of important advan-
tages over complete valve replacement in anatomic valve position.
First, provided that CAVI primarily represents a tool in advancedheart failure, frequently under conditions of impaired right ventricular
(RV) function and pulmonary hypertension (PH), the IVC single-
valve approach provides a safety valve by leaving the superior vena
cava untreated. Also, the majority of patients with heart failure
have transvalvular RV-pacemaker and/or implantable cardioverter-
deﬁbrillator leads, a fact that renders catheter-based valve replace-
ment in anatomic position virtually impossible. In heterotopic IVC
position, however, the leads do not interfere in any way.
The stipulations voiced by Dr. Lauten and colleagues to apply
CAVI only under a condition of normal RV function and
pulmonary vascular resistance are based on an absolutely valid,
established safety approach. At the same time, one can hardly ﬁnd
a patient with this constellation in advanced stages of heart failure.
Our experience, which is admittedly limited, has shown, conversely,
that CAVI can very well be conducted with pathological right-
heart and pulmonary hemodynamics. Indeed, 5 of our 6 patients
exhibited PH (and 2 with systolic pulmonary artery pressure
>60 mm Hg). CAVI did not further increase pulmonary artery
pressure and was well tolerated. Five of the 6 patients suffered from
impaired RV systolic function. In all patients, tricuspid annular
plane systolic excursion signiﬁcantly increased (from a mean of
14.5 mm to 18.6 mm), which indicates partial reversibility of
longitudinal systolic RV function.
Finally, Dr. Lauten and colleagues are correct in stating that in
STR, the FCI diameter is actually too large for the available valve
types. In our patients, the diameters were between 28 and 33 mm,
which meant that direct valve implantation was not possible,
primarily for this reason. Therefore, we prepared a landing zone, with
2 stents implanted 1 over the other. This method enables successful
stabilization and downsizing, and implantation of the 29-mm
Edwards Sapien XT becomes possible. Approximately 10% of the
screened patients had larger diameters (>35 mm) and were not able
to be treated. The occurrence of large vein diameters should actually
prompt design of an appreciably larger dedicated valve.
Dr. Lauten and colleagues request further echo and pressure
parameters to support our concept. The space limitation involved
here in this Reply prevented their presentation; these data will be
included in a publication of ours to appear later.*Michael Laule, MD
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